Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results [Yahoo! Finance]
Eledon Pharmaceuticals, Inc. (ELDN)
Company Research
Source: Yahoo! Finance
the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Reported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation Tegoprubart used as part of immunosuppressive treatment following the first-ever kidney xenotransplant IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its first quarter 2024 operating and financial results and reviewed recent business highlights. “We are pleased with the significant progress made so far this year in the development of tegoprubart for use both in kidney transplantation and in the emerging fields of xenotransplantation and islet cell transplantation. This progress reinforces tegoprubart's potential to become the first-line immunosuppressive treatment option of choice for a broad range of transplant procedures,” said David-Alexandre C. Gros, M.D., Chief Executive Officer
Show less
Read more
Impact Snapshot
Event Time:
ELDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELDN alerts
High impacting Eledon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ELDN
News
- Eledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade [Yahoo! Finance]Yahoo! Finance
- First human to receive transplanted pig kidney dies [Reuters]Reuters
- Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsGlobeNewswire
- Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress [Yahoo! Finance]Yahoo! Finance
- Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant CongressGlobeNewswire
ELDN
Earnings
- 5/9/24 - Beat
ELDN
Analyst Actions
- 3/22/24 - HC Wainwright
ELDN
Sec Filings
- 5/15/24 - Form 10-Q
- 5/13/24 - Form 4
- 5/13/24 - Form 8-K
- ELDN's page on the SEC website